Last reviewed · How we verify
Hydromorphone hydrochloride high dose
At a glance
| Generic name | Hydromorphone hydrochloride high dose |
|---|---|
| Sponsor | Liquan Liang |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Spinal Anesthesia For Enhanced Recovery After Liver Surgery (NA)
- Hydromorphone Hydrochloride Epidural Preemptive Analgesia for Postoperative Pain After Cesarean Section (PHASE4)
- Efficacy and Safety of Oliceridine for Moderate to Severe Acute Pain After Orthopedic Surgery (PHASE4)
- The Evaluation of the Effectiveness and Safety of Nalbuphine Hydrochloride Injection for Analgesia in ICU Patients: A Multicenter, Randomized, Single-blinded, Parallel, Two-step Trial (PHASE2, PHASE3)
- High Dose IV Lidocaine vs Hydromorphone for Abdominal Pain in the Emergency Department (PHASE4)
- Evaluating the Use of Sublingual Sufentanil in Patients With Suboxone Treatment (PHASE4)
- A Trial to Evaluate the Abuse Potential of 3 Doses of GRT6005 in Adult Non-dependent Recreational Opioid Users (PHASE1)
- The Effect of Esketamine on Patients Undergoing Tumor Surgery (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Hydromorphone hydrochloride high dose CI brief — competitive landscape report
- Hydromorphone hydrochloride high dose updates RSS · CI watch RSS
- Liquan Liang portfolio CI